Cardiovascular Effects of lyengar Yoga
林格瑜伽对心血管的影响
基本信息
- 批准号:6813686
- 负责人:
- 金额:$ 19.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-09-15 至 2007-07-31
- 项目状态:已结题
- 来源:
- 关键词:alternative medicinebehavioral /social science research tagbehavioral medicineblood pressurecardiovascular disorder preventioncardiovascular disorder therapyclinical researchclinical trialsheart ratehuman subjecthuman therapy evaluationhypertensionmeditationpatient oriented researchposturepsychophysiologytraining
项目摘要
DESCRIPTION (provided by applicant): Hypertension affects approximately 50 million Americans (24% of the population) and 1 billion individuals worldwide. Hypertension is a potent, consistent and independent risk factor for stroke, heart failure, myocardial infarction and kidney disease. Earlier this year, the Joint National Committee (JNC7) updated its recommendation on the evaluation and management of hypertension. Among the findings of JNC7, the committee emphasized the importance of systolic blood pressure (SBP) and identified a new category of prehypertensive patients who are candidates for effective lifestyle therapies to reduce their cardiovascular risk. Among lifestyle therapies for elevated blood pressure, much of the research to date has been on dietary (low sodium) and activity advice, and dietary supplements (garlic, fish oils). However, mind-body therapies (MBT) such as mediation and yoga are gaining popularity in managing elevations in blood pressure. Yoga is particularly attractive since its popularity and acceptability is rapidly growing in this country, as well as because its multimodal approach, combining postures (asanas), breathing (pranayama) and meditation, lyengar yoga is a particular form of classical therapeutic yoga which relies on tightly scripted asanas which can be standardized, and easily replicated. For this study, we propose to rigorously and scientifically investigate the safety and efficacy of a structured 12 week lyengar Yoga program (IYP) in patients with high-normal to stage I hypertension via a randomized clinical trial using an enhanced usual care comparator group on 3 specific areas. 1) The primary endpoint of this study will be to quantify the effect of the IYP on mean daytime SBP obtained from 24 hour ambulatory blood pressure monitoring (ABPM). 2) The secondary endpoint will be to compare the effects of IYP on heart rate variability (HRV), a measure of cardiac autonomic activity and another important surrogate marker of cardiovascular risk. 3) Finally, we will assess the effects of IYP on physiologic and psychological measures of mood, perceived stress and health related quality of life. By using gold-standard measures of blood pressure and HRV, and collaborating with a network of highly skilled certified lyengar yoga practitioners, we will be able to estimate the true effect of lyengar yoga on SBP, and begin to elucidate mechanisms of this effect. This trial will also generate ample preliminary data for RO1 submissions to allow direct comparisons of lyengar yoga against other non-movement MBTs such as transcendental meditation, established lifestyle recommendations such as the DASH diet, or active pharmacologic control.
描述(由申请人提供):高血压影响约5000万美国人(占人口的24%)和全球10亿人。高血压是中风、心力衰竭、心肌梗死和肾脏疾病的一个强有力的、一致的和独立的危险因素。今年早些时候,联合国家委员会(JNC7)更新了其关于高血压评估和管理的建议。在JNC7的研究结果中,委员会强调了收缩压(SBP)的重要性,并确定了一种新的高血压前期患者类别,这些患者是有效生活方式治疗的候选人,以降低心血管风险。在高血压的生活方式疗法中,迄今为止的大部分研究都是关于饮食(低钠)和活动建议以及膳食补充剂(大蒜,鱼油)。然而,身心疗法(MBT),如调解和瑜伽,在管理血压升高方面越来越受欢迎。瑜伽是特别有吸引力的,因为它的受欢迎程度和可接受性在这个国家迅速增长,以及因为它的多模式方法,结合姿势(体位法),呼吸(呼吸法)和冥想,lyengar瑜伽是一种特殊形式的经典治疗瑜伽,它依赖于严格的脚本体位法,可以标准化,易于复制。在这项研究中,我们建议通过一项随机临床试验,在3个特定领域使用增强的常规护理对照组,严格和科学地调查结构化的12周lyengar瑜伽计划(IYP)在正常高血压至I期高血压患者中的安全性和有效性。1)本研究的主要终点是量化IYP对24小时动态血压监测(ABPM)获得的平均日间收缩压的影响。2)次要终点将是比较IYP对心率变异性(HRV)的影响,心率变异性是心脏自主活动的测量指标,也是心血管风险的另一个重要替代指标。3)最后,我们将评估IYP对情绪,感知压力和健康相关生活质量的生理和心理测量的影响。通过使用血压和心率变异性的金标准测量,并与高技能的认证lyengar瑜伽练习者网络合作,我们将能够估计lyengar瑜伽对SBP的真正影响,并开始阐明这种影响的机制。这项试验还将为RO1提交产生充足的初步数据,以允许直接比较莱因加瑜伽与其他非运动MBT,如超越冥想,建立生活方式建议,如DASH饮食,或积极的药理学控制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIPPE O SZAPARY其他文献
OUTCOMES OF IMAGE-GUIDED THERMAL ABLATION (IGTA) AND STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR PATIENTS WITH PULMONARY METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
- DOI:
10.1016/j.chest.2022.08.1364 - 发表时间:
2022-10-01 - 期刊:
- 影响因子:
- 作者:
ANDRADA NAGHI;PAUL F LAESEKE;CALVIN SH NG;NICOLE FERKO;ALEXANDRA HALL;GEORGE WJ WRIGHT;YUXIN YZ ZHANG;IFTEKHAR KALSEKAR;BALAJI LAXMANAN;SUDIP K GHOSH;MEIJIA ZHOU;PHILIPPE O SZAPARY;MICHAEL A PRITCHETT - 通讯作者:
MICHAEL A PRITCHETT
PHILIPPE O SZAPARY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIPPE O SZAPARY', 18)}}的其他基金
DEVELOPMENT OF THE PHILADELPHIA AREA METABOLIC SYNDROME NETWORK (PAMSYN)
费城地区代谢综合征网络 (PAMSYN) 的发展
- 批准号:
7199124 - 财政年份:2004
- 资助金额:
$ 19.81万 - 项目类别:
FLAXSEED IN REDUCING CARDIOVASCULAR RISK IN PATIENTS W/ PRIMARY HYPERCHOLESTERAL
亚麻籽可降低原发性高胆固醇血症患者的心血管风险
- 批准号:
7199069 - 财政年份:2004
- 资助金额:
$ 19.81万 - 项目类别:
THE EFFECT OF PIOGLITAZONE ON THE HDL-TRIGLYCERIDE AXIS IN NON-DIABETIC PATIENTS
吡格列酮对非糖尿病患者 HDL-甘油三酯轴的影响
- 批准号:
7199070 - 财政年份:2004
- 资助金额:
$ 19.81万 - 项目类别:
Chromium Picolinate in the Metabolic Syndrome
吡啶甲酸铬在代谢综合征中的作用
- 批准号:
6675190 - 财政年份:2003
- 资助金额:
$ 19.81万 - 项目类别:
The Safety and Efficacy of Flaxseed in Reducing Cardiovascular Risk
亚麻籽降低心血管风险的安全性和功效
- 批准号:
7039625 - 财政年份:2003
- 资助金额:
$ 19.81万 - 项目类别:
Anti-Inflammatory, Antiplatelet and Antioxidant Effects of Curcuminoids
姜黄素的抗炎、抗血小板和抗氧化作用
- 批准号:
7039648 - 财政年份:2003
- 资助金额:
$ 19.81万 - 项目类别: